Esophagus

ESOPHAGUS

Feature Article

RFA with ER Effective, Durable Treatment for BE

Emily Pond

Investigators examined short-term and long-term outcomes of patients treated for BE with dysplasia and/or early cancer, according to a uniform protocol.

Latest Articles

LCI for Polyp Detection, Adenomas in Lynch Syndrome

Emily Pond

Investigators compared the use of linked color imaging vs high-definition white light endoscopy for detection of polyps in patients with Lynch syndrome.

Rarely, patients with prostate cancer will develop metastases to the gastrointestinal tract, which l

Adjuvant Nivolumab in Esophageal and GEJ Cancers

Andrea S. Blevins Primeau, PhD, MBA

Residual pathologic disease often remains after neoadjuvant chemotherapy and resection in patients with esophageal or GEJ cancers, and these patients have a high risk of recurrence.

The diagnosis of linitis plastica, a subtype of gastric adenocarcinoma with a poor prognosis, can be

Opdivo Plus Chemotherapy Approved for Treatment of Gastric Cancer

Opdivo (nivolumab) is now approved for the treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Opdivo Plus Chemotherapy Approved for First-Line Treatment of Gastric Cancer

Brian Park, PharmD

Opdivo is a programmed death receptor-1 (PD-1)-blocking antibody.

nCRT With MIE vs nCT With MIE for ESCC

Colby Stong

Researchers compared safety and long-term survival of nCRT followed by MIE vs nCT followed by MIE in patients with advanced ESCC.

RFA Modestly Reduces LGD in Barrett Esophagus

Virginia A. Schad, PharmD, RPh

Researchers aimed to confirm the results of two previous RCTs comparing the effectiveness of radiofrequency ablation vs surveillance in patients with Barrett Oesophagus.

Disinfection With PAA May Reduce Risk of SARS-CoV-2 Spread Following Endoscopy

Brandon May

Investigators examined the effectiveness of the PARP inhibitor olaparib in patients with pancreatic cancer with BRCAness.

tSVFem Delivery for Treatment of Upper GI Lesions

Jessica Nye, PhD

Researchers presented a case series for the use of endoscopic delivery of stromal vascular fraction obtained by mechanical emulsification of autologous adipose tissue in patients with upper GI tract fistulas.

In this study, patients were randomly assigned to receive standard-dose RT or standard-dose RT plus an integrated RT boost to the primary tumor.

Targeting WNT2 Secreted by CAFs May Improve Antitumor T-Cell Response

Emily Pond

Investigators explored the mechanism by which solid tumors appear to resist immune checkpoint inhibitor therapies.

Adjuvant Nivolumab Beneficial in Esophageal, GE Junction Cancer

Among patients with resected esophageal or gastroesophageal junction cancer who have received neoadjuvant chemoradiotherapy, disease-free survival is significantly longer with nivolumab adjuvant therapy versus placebo.

Backlog of Endoscopic Services Will Likely Persist Well Into 2022 in England

Jessica Nye, PhD

Researchers assessed the change in the number of endoscopic procedures due to COVID-19 in England and proposed recovery scenarios based on waiting list volumes.

OSAS May Reduce Incidence of HRE in Patients With LPR

Vincent Soreca

A team of investigators conducted a prospective study to explore the profile of patients with OSAS and LPR at the HEMII-pH and to compare the reflux findings with LPR patients without OSAS.

Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis.

FLIP Effective for Calibration of Partial Fundoplication Construction During LHM.

Vincent Soreca

Investigators evaluated esophagogastric junction distensibility index (EGJ DI) in patients with achalasia at 4 different time points and assessed the association of DI with postoperative outcomes.

Keytruda Plus Chemotherapy Approved as First-Line Tx for Esophageal, GEJ Carcinoma

Diana Ernst, RPh

The approval was based on data from the KEYNOTE-590 study, which evaluated pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy vs placebo plus cisplatin and 5-FU chemotherapy as first-line treatment.

ARS for Long-Term Control of GERD More Effective Than PPI Use.

Jessica Nye, PhD

Researchers assessed the efficacy and cost-effectiveness of proton pump inhibitors vs surgical intervention for acid reflux control.

Allergen Specific IgEs in Classification of Patients With EE

Virginia A. Schad, PharmD, RPh

Investigators analyzed IgE-mediated allergic sensitization patterns in patients with esophageal eosinophilia.

PPI-Resistant Severe Reflux Esophagitis Reduces Saliva Secretion

Jessica Nye, PhD

Investigators examined saliva secretion and salivary epidermal growth factor in patients with proton pump inhibitor-resistant severe reflux esophagitis.